Comparative Pharmacology
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus TRILEPTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus TRILEPTAL.
EXTENDED PHENYTOIN SODIUM vs TRILEPTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
Trileptal (oxcarbazepine) stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting repetitive firing of action potentials. It also modulates high-voltage-activated calcium channels and increases potassium conductance.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
Adults: 600 mg orally twice daily initially; titrate by 600 mg/day every week. Maintenance: 600-1200 mg twice daily.
None Documented
None Documented
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
Parent oxcarbazepine: 1.3–2.3 hours; active metabolite MHD: 8–11 hours (monohydroxy derivative); clinically, the long MHD half-life supports twice-daily dosing.
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Renal excretion is the primary route; 95% of the dose is excreted in urine (79% as MHD, 20% as MHD conjugates, <1% as unchanged oxcarbazepine), and 4% in feces.
Category D/X
Category C
Anticonvulsant
Anticonvulsant